- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.79 Å
- Oligo State
- monomer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 17 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 5 residues within 4Å:- Chain A: G.579, W.669, F.670, Q.673, P.857
Ligand excluded by PLIPEDO.4: 2 residues within 4Å:- Chain A: R.730, Q.765
Ligand excluded by PLIPEDO.5: 4 residues within 4Å:- Chain A: F.419, E.442, M.443, P.499
Ligand excluded by PLIPEDO.6: 7 residues within 4Å:- Chain A: P.262, V.607, F.608, P.610, L.631, S.632, S.633
Ligand excluded by PLIPEDO.7: 3 residues within 4Å:- Chain A: R.642, S.646, W.793
Ligand excluded by PLIPEDO.8: 6 residues within 4Å:- Chain A: S.646, L.648, W.793, H.815, E.817, Q.818
Ligand excluded by PLIPEDO.9: 3 residues within 4Å:- Chain A: W.444, N.842, D.845
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain A: Q.331, E.603, T.629, R.630
Ligand excluded by PLIPEDO.11: 7 residues within 4Å:- Chain A: L.79, S.83, D.84, E.87, R.559, V.562, R.563
Ligand excluded by PLIPEDO.12: 2 residues within 4Å:- Chain A: R.414, E.492
Ligand excluded by PLIPEDO.13: 4 residues within 4Å:- Chain A: W.70, F.71, C.72, E.93
Ligand excluded by PLIPEDO.14: 5 residues within 4Å:- Chain A: Y.147, S.626, I.628, T.629, L.631
Ligand excluded by PLIPEDO.15: 6 residues within 4Å:- Chain A: P.499, C.500, Q.501, F.503, S.520, L.521
Ligand excluded by PLIPEDO.16: 4 residues within 4Å:- Chain A: Y.147, R.149, L.600, N.627
Ligand excluded by PLIPEDO.17: 6 residues within 4Å:- Chain A: I.313, N.314, S.350, R.356, F.636, W.669
Ligand excluded by PLIPEDO.18: 6 residues within 4Å:- Chain A: G.502, F.503, S.504, G.505, T.513, K.549
Ligand excluded by PLIPEDO.19: 4 residues within 4Å:- Chain A: K.689, D.690, L.844
- Chain B: A.2
Ligand excluded by PLIP- 1 x X52: N-(4-{[(3,5-dicyano-4-ethyl-6-{methyl[2-(methylamino)ethyl]amino}pyridin-2-yl)sulfanyl]methyl}phenyl)-N-methylmethanesulfonamide(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pappalardi, M.B. et al., Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer (2021)
- Release Date
- 2021-07-07
- Peptides
- DNA (cytosine-5)-methyltransferase 1: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.79 Å
- Oligo State
- monomer
- Ligands
- 2 x ZN: ZINC ION(Non-covalent)
- 17 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 1 x X52: N-(4-{[(3,5-dicyano-4-ethyl-6-{methyl[2-(methylamino)ethyl]amino}pyridin-2-yl)sulfanyl]methyl}phenyl)-N-methylmethanesulfonamide(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Pappalardi, M.B. et al., Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer (2021)
- Release Date
- 2021-07-07
- Peptides
- DNA (cytosine-5)-methyltransferase 1: A
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
A